Intelligent bio solutions announces fiscal q2 2025 financial results and key operational achievements

Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales submitted fda 510(k) and remain on track for planned expansion into multi-billion dollar u.s. market in 2025 added strategic partnerships, increasing visibility across the asia-pacific region and the u.s. secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries new york, feb. 13, 2025 (globe newswire) -- intelligent bio solutions inc. (nasdaq: inbs) (“inbs” or the “company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal second quarter and six months ended december 31, 2024, and provided a business update. "fiscal q2 was a successful quarter for the business in   a number of   areas.
INBS Ratings Summary
INBS Quant Ranking